The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
Our large-scale pharmacovigilance study identified significant safety signals associated with nivolumab, including previously unrecognized adverse drug reactions. The identification of these safety signals underscores the importance of ongoing post-marketing surveillance for immune checkpoint inhibitors. Future studies should investigate the mechanisms underlying these associations and develop targeted monitoring protocols.
Authors
- Yue Zhou (ORCID: https://orcid.org/0000-0003-0246-3140)
- Yutong Wu (ORCID: https://orcid.org/0000-0002-3659-6892)
- Zhaoyou Meng (ORCID: https://orcid.org/0000-0003-3914-8638)
- Shengli Xia
Institutions
- Army Medical University (CN)
- Xinjiang Medical University (CN)
- Second Affiliated Hospital of Xinjiang Medical University (CN)
- Army Medical College (PK)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-26
- DOI
- https://doi.org/10.3389/fimmu.2025.1605958
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- National Natural Science Foundation of China